# COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

> **NCT04452318** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 3303 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** REGN10933 + REGN10987
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04452318
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-13
- **Primary completion:** 2021-10-04
- **Final completion:** 2021-10-04
- **Target enrollment:** 3303 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04452318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04452318, "COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04452318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*